Abstract:
The present invention related to an oligocycloalkanoid compound comprising formula (I) wherein m, n, and o are independently an integer from 0 to 2; A through A are independently a direct link, alkylene, alkylene-Oâ, carbonyl, oxygen, or sulfur; X and Y are independently hydrogen, hydroxy, alkyl, or in combination an electrophilic group; and R through R are independently hydrogen, hydroxy, alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, N-, S-, or O-heterocycles, fused or multi-ring aryl with or without hetero ring members, arylalkyl, arylalkenyl, arylalkynyl, alkylphenyl, alkenylphenyl, alkynylphenyl, alkoxy, alkenyloxy, alkynyloxy, substituted or unsubstituted aryloxy, substituted or unsubstituted arylalkoxy, alkylacyl, alkenylacyl, alkynylacyl, arylacyl, aroyl, alkylaroyl, aminoaroyl, aminoalkylacyl, aminoalkyl, aminoalkenyl, aminoalkynyl, amino, alkylamino, alkenylamino, alkynylamino, arylamino, dialkylamino, dialkenylamino, dialkynylamino, arylalkylamino, arylalkenylamino, imino, alkylimino, alkenylimino, alkynylimino, arylimino, thiol, sulfoxide, alkyl sulfonamide, alkenyl sulfonamide, alkynyl sulfonamide, aryl sulfonamide, alkyl sulfonate ester, alkenyl sulfonate ester, alkynyl sulfonate ester, aryl sulfonate ester, amino acid, or polypeptide, with at least one of R through R and at least one of R through R being other than hydrogen. Also disclosed are a pharmaceutical composition including an oligocycloalkanoid compound of the present invention, and methods of using such compounds or compositions for treating a bacterial infection, inhibiting or treating septic shock, treating a disease caused by bacterial endotoxin, and inhibiting the activity of cathepsin K.